KNSA
Kiniksa Pharmaceuticals Ltd
Halal Rating :
Last Price
$18.55
Last updated:
Market Cap
-
7D Change
2.09%
1 Year Change
-3.79%
Company Overview
Industries
Exchange
Next Earnings Date
Kiniksa Pharmaceuticals Ltd is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company's primary product is ARCALYST® (rilonacept), which is FDA-approved for the treatment of recurrent pericarditis and other autoinflammatory conditions.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $112.21m | $121.87m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $108.63m | $108.75m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $79.86m | $96.4m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Kiniksa Pharmaceuticals Ltd's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.